Burzynski Research Institute
OverviewSuggest Edit
Burzynski Research Institute (BRI) is a biopharmaceutical company committed to developing, and delivering cancer therapies based on genomic and epigenomic principles. Currently research and development efforts are focused on investigational agents called Antineoplastons (ANPs) and their efficacy and safety in the treatment of advanced cancers, especially malignant brain tumors.
| Type | Public | |
| Founded | 1984 | |
| HQ | Houston, US | Map |
| Website | burzynskiresearch.com |
Locations
Burzynski Research Institute Office Locations
Burzynski Research Institute Financials and Metrics
Burzynski Research Institute Revenue
| USD | |
|---|---|
Net income (Q3, 2020) | (471.7k) |
EBIT (Q3, 2020) | (471.7k) |
Market capitalization (8-Jan-2020) | 1.7m |
Closing stock price (8-Jan-2020) | 0.0 |
Cash (30-Nov-2019) | 221.0 |
| USD | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||
General and administrative expense | 44.1k | 75.5k | 141.5k | 297.1k | 99.2k | 143.8k | 85.6k | 45.2k | 60.4k | 22.3k | 53.2k | 52.1k | 24.6k | 27.0k | 20.3k | 91.7k | 35.0k | 94.7k | 100.6k | 57.7k | 128.8k | 141.2k | 117.6k | 135.6k | 110.5k | 132.0k |
R&D expense | 1.7m | 1.8m | 1.5m | 1.5m | 1.4m | 1.2m | 1.0m | 937.5k | 780.3k | 704.2k | 654.3k | 572.2k | 485.5k | 433.0k | 349.5k | 309.9k | 348.0k | 367.5k | 325.1k | 343.4k | 280.7k | 308.5k | 322.1k | 332.7k | 299.7k | 339.7k |
Operating expense total | 1.8m | 1.8m | 1.7m | 1.8m | 1.5m | 1.4m | 1.1m | 982.7k | 840.7k | 726.5k | 707.5k | 624.4k | 510.1k | 460.0k | 369.8k | 401.6k | 383.0k | 462.2k | 425.7k | 401.1k | 409.6k | 449.7k | 439.6k | 468.3k | 410.2k | 471.7k |
| USD | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 22.5k | 16.1k | 14.9k | 14.1k | 2.6k | 1.3k | 846.0 | 84.0 | 1.9k | 5.8k | 2.0k | 480.0 | 502.0 | 590.0 | 859.0 | 424.0 | 882.0 | 382.0 | 504.0 | 3.4k | 206.0 | 409.0 | 486.0 | 3.1k | 1.1k | 221.0 |
Prepaid Expenses | 32.6k | 16.7k | 44.9k | 33.2k | 9.7k | 45.0k | 32.3k | |||||||||||||||||||
Current Assets | 22.5k | 16.1k | 14.9k | 14.1k | 2.6k | 1.3k | 846.0 | 84.0 | 1.9k | 5.8k | 2.0k | 480.0 | 502.0 | 590.0 | 859.0 | 424.0 | 882.0 | 382.0 | 504.0 | 36.1k | 16.9k | 45.3k | 33.7k | 12.9k | 46.1k | 32.6k |
PP&E | 3.8k | 3.6k | 3.2k | 3.1k | 2.9k | 2.6k | 2.4k | 2.2k | 1.9k | 1.7k | 1.5k | 1.2k | 1.0k | 855.0 | 513.0 | 342.0 | 171.0 |
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|---|
Net Income | (7.2m) | (6.5m) | (4.3m) | (2.9m) | (2.0m) | (1.5m) | (1.6m) | (1.6m) |
Depreciation and Amortization | 701.0 | 683.0 | 684.0 | 684.0 | 684.0 | 684.0 | ||
Accounts Payable | (27.0k) | 35.2k | 66.8k | (14.4k) | (35.5k) | (44.7k) | 22.3k | 59.1k |
Cash From Operating Activities | (504.1k) | (671.3k) | (438.4k) | (353.7k) | (251.0k) | (314.5k) | (319.5k) | (477.5k) |
| USD | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (3.3m) | (5.1m) | (1.7m) | (3.5m) | (5.0m) | (1.4m) | (2.5m) | (3.4m) | (840.9k) | (1.6m) | (2.3m) | (624.5k) | (1.1m) | (1.6m) | (370.0k) | (771.8k) | (1.2m) | (461.2k) | (887.0k) | (1.3m) | (409.6k) | (859.2k) | (1.3m) | (468.3k) | (878.5k) | (1.4m) |
Depreciation and Amortization | 354.0 | 531.0 | 171.0 | 342.0 | 513.0 | 171.0 | 342.0 | 513.0 | 171.0 | 342.0 | 513.0 | 171.0 | 342.0 | 513.0 | 171.0 | 342.0 | 513.0 | |||||||||
Accounts Payable | (36.0k) | (35.6k) | 43.1k | (1.7k) | 40.7k | (7.6k) | 105.5k | 115.6k | (5.9k) | (880.0) | (23.3k) | (18.4k) | (7.1k) | (12.5k) | (18.2k) | 14.2k | (15.5k) | 40.5k | 41.1k | 48.4k | 23.2k | 53.7k | 56.3k | (3.9k) | (8.1k) | (7.0k) |
Cash From Operating Activities | (271.9k) | (388.5k) | (138.9k) | (427.9k) | (538.3k) | (162.6k) | (253.2k) | (340.2k) | (129.0k) | (204.5k) | (317.3k) | (78.6k) | (111.5k) | (157.4k) | (78.0k) | (139.2k) | (230.8k) | (54.6k) | (144.0k) | (213.5k) | (116.3k) | (242.6k) | (371.6k) | (135.8k) | (281.9k) | (430.0k) |
| USD | Y, 2019 |
|---|---|
Financial Leverage | -0.2 x |
Burzynski Research Institute Online and Social Media Presence
Burzynski Research Institute's Trends
Burzynski Research Institute Frequently Asked Questions
When was Burzynski Research Institute founded?
Burzynski Research Institute was founded in 1984.
Who are Burzynski Research Institute competitors?
Competitors of Burzynski Research Institute include Leukos Biotech, BliNK Biomedical and Achilles Therapeutics.
Where is Burzynski Research Institute headquarters?
Burzynski Research Institute headquarters is located at 9432 Katy Fwy, Houston.
Where are Burzynski Research Institute offices?
Burzynski Research Institute has offices in Houston and Stafford.
How many offices does Burzynski Research Institute have?
Burzynski Research Institute has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies